Relmada Therapeutics, Inc (RLMD)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

750 THIRD AVENUE, 9TH FLOOR NEW YORK, NY 10017

Relmada Therapeutics, Inc. is a clinical-stage pharmaceutical company developing novel therapies for the treatment of chronic pain.

Data based on most recent fiscal year report
Market Cap11.107 Million Shares Outstanding12.55 Million Avg Volume25.476 Thousand
1-Yr BETA vs S&P TR0.181 Current Ratio1.79 Quick Ratio1.79
View SEC Filings from RLMD instead.
Q1 2019 All Institutions Hedge Funds 1
To trade RLMD now:
No data found for this quarter.
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding RLMD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

150 Thousand total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KELLY PAUL EDWARD

  • Director
488,483 2019-05-14 4

CASAMENTO CHARLES J

71,500 2019-03-31 1

NOLAN LISA CHIEF BUSINESS OFFICER

23,250 2019-02-28 0

SETH SANDESH CHAIRMAN & CEO

  • Officer
  • Director
161,458 2019-02-21 0

SHENOUDA MAGED CHIEF FINANCIAL OFFICER

62,500 2018-12-28 1

TRAVERSA SERGIO CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2018-12-20 1

VITOLO OTTAVIO V. CHIEF MEDICAL OFFICER

  • Officer
0 2018-12-20 1

BECK DOUGLAS CHIEF FINANCIAL OFFICER

  • Officer
0 2018-11-02 0

AGHARKAR SHREERAM

  • Director
5,759 2015-12-31 0

SALINAS ELISEO ORESTE PRESIDENT AND CSO

  • Officer
0 2015-02-23 0

YAZGI NABIL

  • Director
185,000 2015-01-06 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

KELLY PAUL EDWARD - Director

2019-05-14 P 100,000 $1.50 a 488,483 488,483.00 direct

KELLY PAUL EDWARD - Director

2019-05-14 P 50,000 $2.25 a 50,000 488,483.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments